Keryx Biopharmaceuticals Inc (KERX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

ONE MARINA PARK DR. BOSTON, MA 02210

Acquires, develops and commercializes novel pharmaceutical products for the treatment of life-threatening diseases. As of Dec. 31, 2005, the company's lead product candidates were Sulonex for the treatment of diabetic nephropathy and KRX-0401 for the treatment of multiple forms of cancer.

Data based on most recent fiscal year report
Market Cap478.072 Million Shares Outstanding119.22 Million Avg Volume2.345 Million
1-Yr BETA vs S&P TR Current Ratio3.12 Quick Ratio2.49
View SEC Filings from KERX instead.
Q4 2018 All Institutions Hedge Funds 1
To trade KERX now:
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 1 0 (0.0%)
Aggregate 13F shares on 12/31/2018: 1 0
Aggregate 13F shares on 09/30/2018: 70.595 Million 37.967 Million
Percent change: -100.00% -100.00%
Funds creating new positions:
Funds Adding to an existing position:
Funds closing out their position: 116 21
Funds reducing their position:
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding KERX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HEFFERNAN MICHAEL THOMAS

  • Director
227,362 2019-03-15 2

BUTLER JOHN P. CEO AND PRESIDENT

731,182 2019-02-28 0

GILMAN STEVEN C

0 2019-02-28 4

ENYEDY MARK J CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
483,768 2019-02-22 2

ROGERS MICHAEL W CHIEF FINANCIAL OFFICER

  • Officer
0 2019-02-15 2

KAYE JACK

  • Director
72,707 2019-02-12 0

TARNOK MICHAEL P.

  • Director
188,929 2019-02-12 0

OLIVIERO JAMES F III CEO, PRESIDENT AND DIRECTOR

  • Officer
  • Director
2,135,000 2019-01-24 0

BENTSUR RON CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
38,113 2019-01-01 0

CAMERON KEVIN J

  • Director
No longer subject to file 2018-12-12 5

REGAN DANIEL PAUL

  • Director
No longer subject to file 2018-12-12 2

NEYLAN JOHN F. CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2018-12-12 8

HOLMES SCOTT A CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2018-12-12 7

MORRISON JODIE POPE INTERIM CEO

  • Officer
  • Director
No longer subject to file 2018-12-12 3

CARBERRY CHRISTINE A. CHIEF OPERATING OFFICER

  • Officer
No longer subject to file 2018-12-11 4

BAUPOST GROUP LLC/MA

BAUPOST GROUP GP, L.L.C.

KLARMAN SETH A

  • Director
  • 10% Owner
No longer subject to file 2018-12-11 2

ROSE ERIC A MD

993,094 2018-11-22 0

WEISS MICHAEL S

  • Director
24,663 2018-08-07 0

HOENLEIN MALCOLM

  • Director
78,033 2018-06-06 0

FECZKO JOSEPH M

  • Director
90,517 2018-05-21 0

MADISON GREG PRESIDENT AND CEO

  • Officer
  • Director
566,586 2018-03-20 0

ADAMS BRIAN GENERAL COUNSEL AND SECRETARY

  • Officer
126,069 2018-02-15 0

BAUPOST GROUP LLC/MA

SAK CORP

KLARMAN SETH A

  • 10% Owner
22,268,399 2016-03-15 0

FOWLER WYCHE JR

  • Director
No longer subject to file 2015-06-17 0

HENDERSON CRAIG PRESIDENT

  • Officer
  • Director
0 2007-12-30 0

LEVINE BETH F SVP, GC, CCO AND SECRETARY

  • Officer
0 2007-12-30 0

STIER MARK CHIEF ACCOUNTING OFFICER

  • Officer
0 2007-12-30 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Click here to report any possible errors with this stock listing.

Elevate your investments